Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study

The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-week sub-analysis of the open-label extension of REGAIN (NCT02301624), eculizumab's e...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Murai, H, Uzawa, A, Suzuki, Y, Imai, T, Shiraishi, H, Suzuki, H, Okumura, M, O'Brien, F, Wang, JJ, Fujita, KP, Utsugisawa, K, Study Group, REGAIN, De Bleecker, Jan
Format:	Artikel
Sprache:	eng
Schlagworte:	COMPLEMENT INHIBITOR ECULIZUMAB Eculizumab HLA Japanese patients Medicine and Health Sciences MG-ADL MG-QoL15 Myasthenia gravis ONSET Open-label extension study
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!